News) Temozolomide, a standard treatment
for brain cancer, may boost the aggressiveness
of surviving cancer cells, making tumor
recurrence more likely, a new study suggests.
The research team, from Memorial Sloan-Kettering
Cancer Center in New York City, have identified
cells in brain tumors called gliomas that
have stem cell-like qualities and are able
to survive chemotherapy with the help of
a particular protein. These surviving cells
become drug-resistant, and may be the reason
treatment for brain cancer is usually unsuccessful.
cells are found in brain tumors, and the
mutations that occur in high-grade tumors
promote the stem cell character of tumor
cells," explained lead researcher Dr.
Eric Holland, director of Sloan-Kettering's
Brain Tumor Center. "Furthermore, the
standard therapy for brain tumors -- although
beneficial against many of the tumor cells
-- actually promotes stem cell character
in the cells that survive."
article at: http://health.usnews.com